leadf
logo-loader
viewInnoCan Pharma

Innocan Pharma received U.S. FDA approval for their over the counter CBD pain relief line

Innocan Pharma (CSE: INNO) CEO Iris Bincovich joined Steve Darling from Proactive Vancouver with news the company has just received FDA approval in the United States for their patent-pending CBD Relief &GO pain relief collection.

Bincovich talks about the collection and when they would like to have it in stores and online. She also discussed the latest on their research into Covid-19.

Quick facts: InnoCan Pharma

Price: 0.25 CAD

CSE:INNO
Market: CSE
Market Cap: $43.84 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of InnoCan Pharma named herein, including the promotion by the Company of InnoCan Pharma in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Innocan Pharma bring significant update on Injectable CBD delivery system...

Innocan Pharma (CSE: INNO) CEO Iris Bincovich joined Steve Darling from Proactive with news the company has provided an update on their Injectable CBD delivery system that allows control release. Bincovich telling Proactive some of the recent works done to prove the efficacy of the project...

1 day, 23 hours ago

2 min read